| ID | 1116 | |
| PMID | 19709343 | |
| Year | 2009 | |
| Sequence | AETTNTQQAHTQMSTQ SQDVSYGTYYTIDSNG DYHHTPDGNWNQAMFD NKEYSYTFVDAQGHTH YFYNCYPKNANANGSG QTYVNPATAGDNNDYT ASQSQQHINQYGYQSN VGPDASYYSHSNNNQAY NSHDGNGKVNYPNGTS NQNGGSASKATASGHA KDASWLTSRKQLQPYG QYHGGGAHYGVDYAMP ENSPVYSLTDGTVVQA GWSNYGGGNQVTIKEA NSNNYQWYMHNNRL | |
| Name | Lysostaphin | |
| Length | 291 | |
| N-Terminal Modification | Free | |
| C-Terminal Modification | Free | |
| Linear/ Cyclic | Linear | |
| Chirality | L | |
| Chemical Modification | None | |
| Origin of Peptide | Staphylococcus simulans | |
| Nature of Peptide/Cargo | Endopeptidase,Antimicrobial | |
| Mechanism | It is a glycylglycine endopeptidase, an antibacterial enzyme which is capable of cleaving the crosslinking pentaglycin bridges in the cell wall of Staphylococci | |
| Cargo Sequence/Structure | None | |
| Name of cargo | Not applicable | |
| Assay | Franz diffusion cell | |
| Enhancer | None | |
| Properties of enhancer | Not applicable | |
| Concentration | 10 µl MRSA252 suspension (1·108 CFU ml-1) which was allowed to dry at 25°C; 30 min, 50µl of a treatment solution made up in PBS (1 mg -1l) lysostaphin | |
| Incubation time | 30 minutes | |
| Tissue permeability (value with units) | Lysostaphin (1 mg l-1) caused a 1.95 ± 0.23 log10 CFU reduction in bacteria | |
| Tissue Sample | Abdominal skin from a 38-year-old white female donor | |
| Ex vivo/In vivo/In vitro | ex vivo | |
| STRUCTURE |
| |
| SMILES | N.A. | |